CompanyDeals

HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs

DrugR&D

AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research

CompanyDeals

Hasten Biopharmaceutical Secures $315 Million Investment for Pipeline Expansion

CompanyDeals

Staidson Pharmaceutical Plans RMB 580 Million Private Placement for Drug R&D

CompanyDeals

Sangon Biotech Secures RMB 2 Billion in First Financing Round to Boost Life Science Services

CompanyDeals

Shenzhen 01 Life Science Secures RMB 100 Million in Series B1 Financing for Microecology Platform

CompanyDrug

Pfizer’s Prevenar 13 Receives Expanded Age Range Approval in China

CompanyDrug

BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer

CompanyDeals

Zylox-Tonbridge Medical Teams Up with Hicicare Science for Guide Wire Product Sales in China

CompanyDeals

Shanghai Ark Biopharmaceutical’s STAR Market IPO Filing Accepted, Aims to Raise $289.6 Million

CompanyDrug

Hunan Warrant Pharmaceutical Receives NMPA Approval for Generic Brivudine

CompanyDrug

Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC